Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

760.13 -4.58 (-0.60%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
The biopharmaceutical company has an exciting lead compound in development. 
Via The Motley Fool
1 Reason to Buy Eli Lilly (LLY) Stock
There's a reason you might want to hold off on buying Lilly stock. 
Via The Motley Fool
Topics Government World Trade
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'
Cramer says we are "too negative" on Eli Lilly. "I think they should come back on and talk to me," he adds. 
Via Benzinga
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today
Eli Lilly stock plummeted after its recent earnings report, but it's been a long-term winner for investors. 
Via The Motley Fool
Novo Nordisk Stock: Buy or Sell?
News from a competitor is increasing enthusiasm for Novo Nordisk stock. 
Via The Motley Fool
LLY Q2 Deep Dive: Weight Loss Pill Data and Channel Dynamics Spur Investor Uncertainty
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 37.6% year on year to $15.56 billion. The company’s full-year... 
Via StockStory
Topics World Trade
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit of... 
Via StockStory
Topics Economy
Why Eli Lilly Stock Popped Today
Eli Lilly stock got cheaper last week. Investors now get a second bite at the delicious GLP-1 apple. 
Via The Motley Fool
S&P 500 Earnings Season Concludes with Robust Performance, Signaling Corporate Resilience
As the curtain falls on another corporate earnings season, the S&P 500 has delivered a performance that has largely exceeded initial expectations, painting a picture of surprising corporate health... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Unusual volume S&P500 stocks in Monday's session
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the... 
Via StockStory
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
3 Top Stocks to Load Up on After Earnings
Here are three stocks to buy now that could offer investors upside in the short and long terms. 
Via The Motley Fool
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly. 
Via Benzinga
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly and Company reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines. However, shares of Eli Lilly stock tumbled 14%. Here are ETFs with... 
Via Talk Markets
Topics ETFs
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy
The past week saw market turbulence, with President Trump's new gold tariffs, Eli Lilly's dramatic stock drop, a weakening jobs report fueling recession fears, and a divided Federal Reserve debating... 
Via Benzinga
Topics Economy Government World Trade
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Why Eli Lilly Stock Sank 18% This Week
The drugmaker is in a 35% drawdown. 
Via The Motley Fool
Topics World Trade
Apple Notches Best Week In Years, Trump Shakes Fed Leadership: This Week In Markets
After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat. 
Via Benzinga
Topics Economy Government World Trade
Wall Street's Resilient Rally: What's Driving the Positive Momentum
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
Expert Outlook: Eli Lilly Through The Eyes Of 4 Analysts
 
Via Benzinga
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength. 
Via Benzinga
In today's session, there are S&P500 stocks with remarkable trading volume.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
SoundHound Stock Rallies On Huge Revenue Jump
SoundHound stock rallied Friday after the conversational AI technology company posted a huge gain in revenue. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.